Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma

Oncotarget

Volumn 6, Issue 34, 2015, Pages 35247-35262

  Bogen, Dominik ^a,b   Wei, Jun S ^a   Azorsa, David O ^d   Ormanoglu, Pinar ^c   Buehler, Eugen ^c   Guha, Rajarshi ^c   Keller, Jonathan M ^c   Mathews Griner, Lesley A ^c   Ferrer, Marc ^c   Song, Young K ^a   Liao, Hongling ^a   Mendoza, Arnulfo ^a   Gryder, Berkley E ^a   Sindri, Sivasish ^a   He, Jianbin ^a   Wen, Xinyu ^a   Zhang, Shile ^a   Shern, John F ^a   Yohe, Marielle E ^a   Taschner Mandl, Sabine ^b   Shohet, Jason M ^e   Thomas, Craig J ^c   Martin, Scott E ^c   Ambros, Peter F ^b   Khan, Javed ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^e CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

AURKB; Barasertib; High throughput screening; MYCN; Neuroblastoma

Indexed keywords

AURORA B KINASE; AURORA KINASE INHIBITOR; BARASERTIB; CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HISTONE H3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P53; SMALL INTERFERING RNA; SURVIVIN; TRANSCRIPTION FACTOR E2F1; MOLECULAR LIBRARY; PROTEIN KINASE INHIBITOR;

ANIMAL MODEL; APOPTOSIS; ARTICLE; BIRC5 GENE; CANCER INHIBITION; CANCER SURVIVAL; CDCA8 GENE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CHEK1 GENE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; ENZYME INHIBITION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC SELECTION; HEC1 GENE; HIGH THROUGHPUT SCREENING; HUMAN; KIF11 GENE; M PHASE CELL CYCLE CHECKPOINT; MOUSE; MYCN GENE; NDC80 GENE; NEUROBLASTOMA; NEUROBLASTOMA CELL LINE; NONHUMAN; NUF2 GENE; PLK1 GENE; PROMOTER REGION; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RACGAP1 GENE; RNA INTERFERENCE; TTK GENE; TUMOR GENE; TUMOR REGRESSION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; GENE SILENCING; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; MOLECULAR LIBRARY; MOLECULARLY TARGETED THERAPY; NONOBESE DIABETIC MOUSE; PHARMACOLOGY; PHYSIOLOGY; PROCEDURES; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; AURORA KINASE B; CELL LINE, TUMOR; FEMALE; GENE KNOCKDOWN TECHNIQUES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MOLECULAR TARGETED THERAPY; NEUROBLASTOMA; PROTEIN KINASE INHIBITORS; RNA INTERFERENCE; SMALL MOLECULE LIBRARIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84946893386     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6208     Document Type: Article

References (61)

1. Maris JM. Recent advances in neuroblastoma. The New England journal of medicine. 2010; 362:2202-2211.
2. Smith MA, Seibel NL, Altekruse SF, Ries LAG, Melbert DL, O'Leary M, Smith FO and Reaman GH. Outcomes for Children and Adolescents With Cancer: Challenges for the Twenty-First Century. Journal of Clinical Oncology. 2010; 28:2625-2634.
3. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB and Villablanca JG. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27:1007-1013.
4. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W and Robison LL. Chronic health conditions in adult survivors of childhood cancer. The New England journal of medicine. 2006; 355:1572-1582.
5. Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, Laudenslager M, Rappaport EF, Wood AC, McGrady PW, Hogarty MD, London WB, Radhakrishnan R, et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer cell. 2014; 26:682-694.
6. Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A, Matthay KK, Rowitch D and Weiss WA. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer research. 2006; 66:8139-8146.
7. Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N, Kenney AM, Schulte JH, Beijersbergen R, Christiansen H, Berwanger B and Eilers M. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer cell. 2009; 15:67-78.
8. Gustafson WC, Meyerowitz JG, Nekritz EA, Chen J, Benes C, Charron E, Simonds EF, Seeger R, Matthay KK, Hertz NT, Eilers M, Shokat KM and Weiss WA. Drugging MYCN through an Allosteric Transition in Aurora Kinase A. Cancer cell. 2014; 26:414-427.
9. Reynolds CP, Kang MH, Carol H, Lock R, Gorlick R, Kolb EA, Kurmasheva RT, Keir ST, Maris JM, Billups CA, Houghton PJ and Smith MA. Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatric blood & cancer. 2013; 60:791-798.
10. Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Wu J, Smith MA and Houghton PJ. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatric blood & cancer. 2010; 55:26-34.
11. Marine S, Bahl A, Ferrer M and Buehler E. Common seed analysis to identify off-target effects in siRNA screens. Journal of biomolecular screening. 2012; 17:370-378.
12. Konig R, Chiang CY, Tu BP, Yan SF, DeJesus PD, Romero A, Bergauer T, Orth A, Krueger U, Zhou Y and Chanda SK. A probability-based approach for the analysis of large-scale RNAi screens. Nature methods. 2007; 4:847-849.
13. Buehler E, Khan AA, Marine S, Rajaram M, Bahl A, Burchard J and Ferrer M. siRNA off-target effects in genome-wide screens identify signaling pathway members. Scientific reports. 2012; 2:428.
14. Carmena M, Wheelock M, Funabiki H and Earnshaw WC. The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis. Nature reviews Molecular cell biology. 2012; 13:789-803.
15. Mathews LA, Keller JM, Goodwin BL, Guha R, Shinn P, Mull R, Thomas CJ, de Kluyver RL, Sayers TJ and Ferrer M. A 1536-well quantitative high-throughput screen to identify compounds targeting cancer stem cells. Journal of biomolecular screening. 2012; 17:1231-1242.
16. Brockmann M, Poon E, Berry T, Carstensen A, Deubzer HE, Rycak L, Jamin Y, Thway K, Robinson SP, Roels F, Witt O, Fischer M, Chesler L, et al. Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer cell. 2013; 24:75-89.
17. Murphy DM, Buckley PG, Bryan K, Watters KM, Koster J, van Sluis P, Molenaar J, Versteeg R and Stallings RL. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. Molecular carcinogenesis. 2011; 50:403-411.
18. Shohet JM, Ghosh R, Coarfa C, Ludwig A, Benham AL, Chen Z, Patterson DM, Barbieri E, Mestdagh P, Sikorski DN, Milosavljevic A, Kim ES and Gunaratne PH. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma. Cancer research. 2011; 71:3841-3851.
19. Gully CP, Velazquez-Torres G, Shin JH, Fuentes-Mattei E, Wang E, Carlock C, Chen J, Rothenberg D, Adams HP, Choi HH, Guma S, Phan L, Chou PC, et al. Aurora B kinase phosphorylates and instigates degradation of p53. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:E1513-1522.
20. Gizatullin F, Yao Y, Kung V, Harding MW, Loda M and Shapiro GI. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer research. 2006; 66:7668-7677.
21. Hilton JF and Shapiro GI. Aurora kinase inhibition as an anticancer strategy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2014; 32:57-59.
22. Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, Byth KF, Barrass NC, Mundt KE, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007; 13:3682-3688.
23. Gully CP, Zhang F, Chen J, Yeung JA, Velazquez-Torres G, Wang E, Yeung SC and Lee MH. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Molecular cancer. 2010; 9:42.
24. Houghton PJ, Morton CL, Kolb EA, Lock R, Carol H, Reynolds CP, Keshelava N, Maris JM, Keir ST, Wu J and Smith MA. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatric blood & cancer. 2008; 50:37-45.
25. Carol H, Lock R, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Billups CA and Smith MA. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatric blood & cancer. 2009; 53:1255-1263.
26. Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, Diskin SJ, Attiyeh EF, Sennett R, Norris G, Laudenslager M, Wood AC, Mayes PA, et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108:3336-3341.
27. Mosse YP, Lipsitz E, Fox E, Teachey DT, Maris JM, Weigel B, Adamson PC, Ingle MA, Ahern CH and Blaney SM. Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18:6058-6064.
28. Gorlick R, Kolb EA, Keir ST, Maris JM, Reynolds CP, Kang MH, Carol H, Lock R, Billups CA, Kurmasheva RT, Houghton PJ and Smith MA. Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. Pediatric blood & cancer. 2014; 61:158-164.
29. Morozova O, Vojvodic M, Grinshtein N, Hansford LM, Blakely KM, Maslova A, Hirst M, Cezard T, Morin RD, Moore R, Smith KM, Miller F, Taylor P, et al. System-level analysis of neuroblastoma tumor-initiating cells implicates AURKB as a novel drug target for neuroblastoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010; 16:4572-4582.
30. Sos ML, Dietlein F, Peifer M, Schottle J, Balke-Want H, Muller C, Koker M, Richters A, Heynck S, Malchers F, Heuckmann JM, Seidel D, Eyers PA, et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:17034-17039.
31. Yang D, Liu H, Goga A, Kim S, Yuneva M and Bishop JM. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107:13836-13841.
32. Faisal A, Vaughan L, Bavetsias V, Sun C, Atrash B, Avery S, Jamin Y, Robinson SP, Workman P, Blagg J, Raynaud FI, Eccles SA, Chesler L, et al. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Molecular cancer therapeutics. 2011; 10:2115-2123.
33. Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, Perini G, Lunec J and Tweddle DA. p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer research. 2010; 70:1377-1388.
34. Shimada H, Stram DO, Chatten J, Joshi VV, Hachitanda Y, Brodeur GM, Lukens JN, Matthay KK and Seeger RC. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. Journal of the National Cancer Institute. 1995; 87:1470-1476.
35. Tweddle DA, Pearson AD, Haber M, Norris MD, Xue C, Flemming C and Lunec J. The p53 pathway and its inactivation in neuroblastoma. Cancer letters. 2003; 197:93-98.
36. Carr-Wilkinson J, O'Toole K, Wood KM, Challen CC, Baker AG, Board JR, Evans L, Cole M, Cheung NK, Boos J, Kohler G, Leuschner I, Pearson AD, et al. High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010; 16:1108-1118.
37. Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A and Shohet JM. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102:731-736.
38. Corvi R, Savelyeva L, Breit S, Wenzel A, Handgretinger R, Barak J, Oren M, Amler L and Schwab M. Nonsyntenic amplification of MDM2 and MYCN in human neuroblastoma. Oncogene. 1995; 10:1081-1086.
39. Marxer M, Ma HT, Man WY and Poon RY. p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases. Oncogene. 2014; 33:3550-3560.
40. McKenzie PP, Guichard SM, Middlemas DS, Ashmun RA, Danks MK and Harris LC. Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damageinduced G1 checkpoint function is attenuated. Clinical cancer research: an official journal of the American Association for Cancer Research. 1999; 5:4199-4207.
41. Bell E, Premkumar R, Carr J, Lu X, Lovat PE, Kees UR, Lunec J and Tweddle DA. The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage. Cell Cycle. 2006; 5:2639-2647.
42. Azzariti A, Bocci G, Porcelli L, Fioravanti A, Sini P, Simone GM, Quatrale AE, Chiarappa P, Mangia A, Sebastian S, Del Bufalo D, Del Tacca M and Paradiso A. Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. British journal of cancer. 2011; 104:769-780.
43. Evans RP, Naber C, Steffler T, Checkland T, Maxwell CA, Keats JJ, Belch AR, Pilarski LM, Lai R and Reiman T. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. British journal of haematology. 2008; 140:295-302.
44. Ikezoe T, Takeuchi T, Yang J, Adachi Y, Nishioka C, Furihata M, Koeffler HP and Yokoyama A. Analysis of Aurora B kinase in non-Hodgkin lymphoma. Laboratory investigation; a journal of technical methods and pathology. 2009; 89:1364-1373.
45. Nair JS, de Stanchina E and Schwartz GK. The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15:2022-2030.
46. Oke A, Pearce D, Wilkinson RW, Crafter C, Odedra R, Cavenagh J, Fitzgibbon J, Lister AT, Joel S and Bonnet D. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer research. 2009; 69:4150-4158.
47. Tao Y, Zhang P, Girdler F, Frascogna V, Castedo M, Bourhis J, Kroemer G and Deutsch E. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152. Oncogene. 2008; 27:3244-3255.
48. Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, Komatsu N, Bandobashi K, Togitani K, Koeffler HP, Taguchi H and Yokoyama A. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood. 2007; 110:2034-2040.
49. Mori N, Ishikawa C, Senba M, Kimura M and Okano Y. Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas. Biochemical pharmacology. 2011; 81:1106-1115.
50. Boss DS, Witteveen PO, van der Sar J, Lolkema MP, Voest EE, Stockman PK, Ataman O, Wilson D, Das S and Schellens JH. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2011; 22:431-437.
51. Dennis M, Davies M, Oliver S, D'Souza R, Pike L and Stockman P. Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia. Cancer chemotherapy and pharmacology. 2012; 70:461-469.
52. Lowenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahn JY, Ifrah N, Martinelli G, Amadori S, Berman E, Sonneveld P, Jongen-Lavrencic M, Rigaudeau S, Stockman P, et al. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood. 2011; 118:6030-6036.
53. Schwartz GK, Carvajal RD, Midgley R, Rodig SJ, Stockman PK, Ataman O, Wilson D, Das S and Shapiro GI. Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Investigational new drugs. 2013; 31:370-380.
54. Tsuboi K, Yokozawa T, Sakura T, Watanabe T, Fujisawa S, Yamauchi T, Uike N, Ando K, Kihara R, Tobinai K, Asou H, Hotta T and Miyawaki S. A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia. Leukemia research. 2011; 35:1384-1389.
55. Collins G, Eyre T, Hatton C, Radford J and Linton K. A Phase 2 Trial of AZD1152 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. ASH Annual Meeting and Exposition. 2014; 56:4481.
56. Kantarjian HM, Martinelli G, Jabbour EJ, Quintas-Cardama A, Ando K, Bay JO, Wei A, Gropper S, Papayannidis C, Owen K, Pike L, Schmitt N, Stockman PK, et al. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer. 2013; 119:2611-2619.
57. Azorsa DO, Gonzales IM, Basu GD, Choudhary A, Arora S, Bisanz KM, Kiefer JA, Henderson MC, Trent JM, Von Hoff DD and Mousses S. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. Journal of translational medicine. 2009; 7:43.
58. Chung N, Zhang XD, Kreamer A, Locco L, Kuan PF, Bartz S, Linsley PS, Ferrer M and Strulovici B. Median absolute deviation to improve hit selection for genome-scale RNAi screens. Journal of biomolecular screening. 2008; 13:149-158.
59. Li B and Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC bioinformatics. 2011; 12:323.
60. Mathews LA, Guha R, Shinn P and Lim KH. Highthroughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill ABC diffuse large B-cell lymphoma cells. PNAS. 2013.
61. Wang Y, Jadhav A, Southal N, Huang R and Nguyen DT. A grid algorithm for high throughput fitting of dose-response curve data. Current chemical genomics. 2010; 4:57-66.